Furthermore, these findings offer valuable insights for potentially developing a tumor vaccine for BCR-ABL1+ B-ALL, where the immunogenic effects of the CD19@NP/17-DMAG system could be harnessed to induce durable T-cell memory as a safeguard against disease recurrence. Here, CD19 is linked to neoplasm.